DALLAS, April 28 /PRNewswire/ -- BeaconEquity.com announces the availability of Stock Alerts on stocks making news today. As the influenza dominates the headlines, several biopharmaceutical stocks are parading up the charts.

NEW YORK - Dynavax Technologies Corp. stock surged to an all-time high Wednesday, a day after the drug developer released positive late-stage trial data for its hepatitis B vaccine, Heplisav. Shares of Dynavax rose $2.3901, or 32.3 percent, to close at $9.79 on the Nasdaq Stock Market.